NuPathe Announces $8.5M Term Loan

by Paul Quintaro, Benzinga Editor
November 27, 2012 8:06 AM | 14 seconds read |
NuPathe Inc. PATH, a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that it has entered into a $8.5 million term loan agreement with Hercules Technology Growth Capital.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFinancing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!